NewsBenzingaCoya Therapeutics : le BPA du T3 à (0,45 $) est inférieur à l’estimation de (0,34 $), les ventes de 234,134 k$ dépassent l’estimation de 85,714 k$ Coya Therapeutics : le BPA du T3 à (0,45 $) est inférieur à l’estimation de (0,34 $), les ventes de 234,134 k$ dépassent l’estimation de 85,714 k$ Benzinga 2026.11.10 13:07 (GMT+0) Open on Benzinga Other news Swoosh and a Miss: Nike Investor Day Leaves Wall Street Cold-Footed Wall Street Says the AI Trade Is Over — ETF Investors Aren’t Acting Like It Citigroup Maintains Neutral on Westlake, Lowers Price Target to $65 Citigroup Maintains Neutral on LyondellBasell Industries, Lowers Price Target to $66 Caterpillar's 'Best-In-Class' Construction Business Is Getting Overlooked, Analyst Says How to Play NKE Stock as Nike Risks Becoming a Forever Turnaround Story